Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[NSAIDs digestive risk: epidemiologic data].

Philippe Ravaud1, Stanislas Chaussade

  • 1Département d'épidémiologie, biostatistique et recherche clinique, Hôpital Bichat, Paris.

Presse Medicale (Paris, France : 1983)
|February 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing the trustworthiness of non-randomized studies of interventions: a survey of international experts.

BMC medicine·2026
Same author

Heterogeneity of information across seven curated national or international digital health app repositories.

Digital health·2026
Same author

Building evidence on digital psychotherapies for adults living with depression: a systematic scoping review of populations, interventions and design features of ongoing and planned randomised controlled trials.

BMJ mental health·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same author

Mapping the evidence supporting FDA-authorized digital therapeutics, before and after authorization.

NPJ digital medicine·2026
Same author

A scoping review of ICHOM sets identifies a small number of commonly recommended baseline characteristics.

Journal of clinical epidemiology·2026
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Conventional non-steroidal anti-inflammatory drugs (NSAIDs) significantly increase gastrointestinal risks like ulcers and bleeding. This risk persists even after discontinuing NSAID treatment, posing a long-term danger to patients.

Area of Science:

  • Gastroenterology and Pharmacology
  • Drug Safety and Risk Assessment

Context:

  • Conventional non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for pain and inflammation.
  • NSAID use is associated with a substantial increase in gastrointestinal (GI) adverse events, including ulcers and bleeding.

Purpose:

  • To highlight the significant gastrointestinal risks associated with conventional NSAID use.
  • To inform about the persistent risk of GI complications even after NSAID cessation.

Summary:

  • Conventional NSAIDs elevate the risk of secondary GI adverse effects, such as ulcers and bleeding, by approximately fourfold.
  • An estimated 1220 patients require treatment with NSAIDs for over two months to observe a potentially fatal outcome.
  • The GI risk associated with NSAIDs remains constant during treatment and persists for at least three months post-discontinuation.

Related Experiment Videos

Impact:

  • Emphasizes the critical need for careful patient selection and monitoring during NSAID therapy.
  • Underscores the importance of considering alternative pain management strategies to mitigate GI risks.
  • Informs clinical practice regarding the prolonged safety considerations after NSAID treatment withdrawal.